

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626KAS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 25	CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS	4	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	5	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	6	FEB 28	MEDLINE/IMEDLINE reloaded
NEWS	7	MAR 02	GBFULL: New full-text patent database on STN
NEWS	8	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	9	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	10	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	11	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	12	MAR 22	PATDPASPC - New patent database available
NEWS	13	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	14	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	15	APR 04	EMBASE - Database reloaded and enhanced
NEWS	16	APR 18	New CAS Information Use Policies available online
NEWS	17	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAPLUS and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	18	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAPLUS
NEWS	19	MAY 23	GBFULL enhanced with patent drawing images
NEWS	20	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	21	MAY 26	STN User Update to be held June 6 and June 7 at the SLA 2005 Annual Conference
NEWS EXPRESS			JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:37:26 ON 30 MAY 2005

=> ile reg

ILE IS NOT A RECOGNIZED COMMAND

The previous command.name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:37:37 ON 30 MAY 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 29 MAY 2005 HIGHEST RN 851364-46-0

DICTIONARY FILE UPDATES: 29 MAY 2005 HIGHEST RN 851364-46-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more  
information enter HELP PROP at an arrow prompt in the file or refer  
to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10760125.str

10760125



chain nodes :

6 7 8 9 10 11 12 13 14 15 16 17 18 19 26

ring nodes :

1 2 3 4 5 20 21 22 23 24 25

chain bonds :

1-6 6-7 7-8 7-9 8-10 10-11 11-12 11-26 12-13 13-14 13-19 14-15 14-16  
16-17 17-18 19-20

ring bonds :

1-2 1-5 2-3 3-4 4-5 20-21 20-25 21-22 22-23 23-24 24-25

exact/norm bonds :

1-2 1-5 1-6 7-8 7-9 8-10 11-12 11-26 12-13 14-15 16-17 17-18

exact bonds :

2-3 3-4 4-5 6-7 10-11 13-14 13-19 14-16 19-20

normalized bonds :

20-21 20-25 21-22 22-23 23-24 24-25

isolated ring systems :

containing 1 : 20 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS  
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS  
18:CLASS 19:CLASS 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS


L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

10760125



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 12:37:58 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS  
SEARCH TIME: 00.00.01

3 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 4 TO 200  
PROJECTED ANSWERS: 3 TO 163

L2 3 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 12:38:06 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 47 TO ITERATE

100.0% PROCESSED 47 ITERATIONS  
SEARCH TIME: 00.00.01

34 ANSWERS

L3 34 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
161.33	161.54

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 12:38:11 ON 30 MAY 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 May 2005 VOL 142 ISS 23  
FILE LAST UPDATED: 29 May 2005 (20050529/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4                    6 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2005 ACS ON STN

ACCESSION NUMBER:

DOCUMENT NUMBER:

TITLE:

2000:769109 CAPLUS

133:322130

Synthesis of benzo-fused heterocyclic sulfonyl chlorides for preparation of amino acid hydroxyethylamine sulfonamide retroviral protease inhibitors

INVENTOR(S):

Kunda, Sastry A.; Letendre, Leo J.; De Crescenzo, Gary A.

PATENT ASSIGNEE(S):

G.D. Searle and Co., USA

SOURCE:

U.S., 95 pp., Cont.-in-part of U.S. 5,756,533.

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6140505	A	20001031	US 1998-80928	19980519
US 5765533	A	19980526	US 1995-474052	19950607
EP 1258491	A1	20021120	EP 2002-11526	19960307
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
WO 9959989	A1	19991125	WO 1999-US7047	19990518
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TH, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9938604	A1	19991206	AU 1999-38604	19990518
US 6310080	B1	20011030	US 1999-451920	19991201
US 2002111368	A1	20020815	US 2001-836443	20010418
US 6458785	B2	20021001		
US 2003216435	A1	20031120	US 2002-200589	20020723
US 6730669	B2	20040504		
US 2004260095	A1	20041223	US 2004-760125	20040120

PRIORITY APPLN. INFO.:

OTHER SOURCE(S):

CASREACT 133:322130; MARPAT 133:322130

AB Benzo-fused heterocyclic sulfonyl halides for the preparation of amino acid hydroxyethylamine sulfonamide retroviral protease inhibitors were obtained by a process comprising reacting a benzo-fused heterocyclic compound with an SO<sub>3</sub> complex in the presence of a water immiscible, non-reactive solvent at 0-75°, cooling, if necessary, to a temperature of from about -25°

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)

to about 65° and then adding oxaly halide. Thus, N-(2R-hydroxy-3-[[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2S-[[pyrrolidin-1-yl]acetyl]amino)-3,3-dimethylbutanamide was prepd. and shown to be an effective HIV protease inhibitor (IC<sub>50</sub> = 3 nM, EC<sub>50</sub> = 7 nM).

IT


183812-50-2P 183812-51-3P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(synthesis of benzo-fused heterocyclic sulfonyl chlorides for preparation of amino acid hydroxyethylamine sulfonamide retroviral protease inhibitors)

RN 183812-50-2 CAPLUS

CN 1-Pyrrolidineacetamide, N-[(1R)-2-[[[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-1-(methylsulfonyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183812-51-3 CAPLUS

CN 1-Pyrrolidineacetamide, N-[(1R)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methyl-2-(methylsulfonyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 174303-65-2P 183553-66-4P 183553-78-8P

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)

183553-82-4P 183553-86-8P 183554-03-2P

183554-04-3P 183554-05-4P 183554-07-6P


183594-99-2P 183812-53-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(synthesis of benzo-fused heterocyclic sulfonyl chlorides for prepn. of amino acid hydroxyethylamine sulfonamide retroviral protease inhibitors)

RN 174303-65-2 CAPLUS

CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183553-66-4 CAPLUS

CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183553-78-8 CAPLUS

CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



RN 183553-82-4 CAPLUS

CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183553-86-8 CAPLUS

CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183554-03-2 CAPLUS

CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)sulfonyl]amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 183554-04-3 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183554-05-4 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(2,3-dihydro-5-benzofuranyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183554-07-6 CAPLUS

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

IT 183553-47-1P 183553-87-9P 183553-89-1P  
 183553-94-8P 183554-15-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (synthesis of benzo-fused heterocyclic sulfonyl chlorides for preparation of amino acid hydroxyethylamine sulfonamide retroviral protease inhibitors)


RN 183553-47-1 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183553-87-9 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183553-89-1 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1R)-2-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-1-[(methylsulfonyl)methyl]-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-3-butynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183594-99-2 CAPLUS  
 CN Carbanic acid, [5-[[[(2R,3S)-[3-[[[(2S)-3,3-dimethyl-1-oxo-2-[(1-pyrrolidinyl)acetyl]amino]butyl]amino]-2-hydroxy-4-phenylbutyl]-(2-methylpropyl)amino]sulfonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183812-53-5 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 183553-94-8 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1R)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methyl-2-(methylsulfonyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 183554-15-6 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● 2 HCl


REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:753229 CAPLUS  
 DOCUMENT NUMBER: 132:6692  
 TITLE: benzo fused heterocyclic sulfonyl halide intermediates for the preparation of amino acids as HIV protease inhibitors  
 INVENTOR(S): Kunda, Sastry A.; Letendre, Leo J.; De Crescenzo, Gary A.  
 PATENT ASSIGNEE(S): G.D. Searle and Co., USA  
 SOURCE: PCT Int. Appl., 221 pp.  
 CODEN: PIXKD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 5  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9959989	A1	19991125	WO 1999-057047	19990518
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GR, GU, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6140505	A	20001031	US 1998-80928	19980519
AU 9938604	A1	19991206	AU 1999-38604	19990518
US 2002111368	A1	20020815	US 2001-836443	20010418
US 6458785	B2	20021001		
PRIORITY APPL. INFO.:				
			US 1998-80928	A1 19980519
			US 1995-402287	B2 19950310
			US 1995-474052	A2 19950607
			WO 1999-057047	W 19990518
			US 1999-451920	A3 19991201

OTHER SOURCE(S): MARPAT 132:6692  
 GI



AB Sulfonamide amino acids I (R1 = alkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cyanoalkyl, imidazolylmethyl, CH2CONH2, CH2CH2CONH2, CH2SO2NH2, CH2SMe, CH2SOMe, CH2SO2Me, CH2SMe, CH2SOMe; R2 = alkyl, alkylthioalkyl, arylthioalkyl, cycloalkyl; R3 = alkyl, cycloalkyl, cycloalkylalkyl; R4 = substituted heterocycle, R5 = H, alkyl,

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 hydroxyalkyl, alkoxyalkyl; R6 = H, alkyl, hydroxyalkyl, alkoxyalkyl, alkylamide, sulfone, alkylthioalkyl; R7-R9 = H, substituted heterocycle, benzo) were prepd. as HIV protease inhibitors. Process for prep. a benzo fused heterocyclic sulfonyl halide intermediate, comprising reacting a benzo fused heterocyclic compd. with a -SO3- complex in the presence of a solvent and then adding oxalyl halide. Thus, amino acid I (R1 = CHMeEt, R2 = Bn, R3 = CH2CHMe3, R4 = Ph, R5-E9 = H, n = 1) was prepd. and tested as HIV protease inhibitor (IC50 = 4 nM).

IT 174303-65-2P 183553-47-1P 183553-66-4P  
 183553-78-8P 183553-82-4P 183553-86-8P  
 183553-87-9P 183553-89-1P 183553-94-8P  
 183554-03-2P 183554-04-3P 183554-05-4P  
 183554-07-6P 183554-15-6P 183594-99-2P  
 183812-53-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(benzo fused heterocyclic sulfonyl halide intermediates for the

preparation of amino acids as HIV protease inhibitors)

RN 174303-65-2 CAPLUS

CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl) (2-methylpropyl) amino]-2-hydroxy-1-(phenylmethyl)propyl] amino] carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183553-47-1 CAPLUS

CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl) (2-methylpropyl) amino]-2-hydroxy-1-(phenylmethyl)propyl] amino] carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183553-66-4 CAPLUS

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl) amino]-1-(phenylmethyl)propyl] amino] carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183553-78-8 CAPLUS

CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl) (2-methylpropyl) amino]-2-hydroxy-1-(phenylmethyl)propyl] amino] carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183553-82-4 CAPLUS

CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl) (2-methylpropyl) amino]-2-hydroxy-1-(phenylmethyl)propyl] amino] carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183553-86-8 CAPLUS

CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl) amino]-1-




L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183553-87-9 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183553-89-1 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1R)-2-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-1-[(methylsulfonyl)methyl]-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 183554-04-3 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183554-05-4 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[[[(2,3-dihydro-5-benzofuranyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183554-07-6 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-3-butynyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 183553-94-8 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1R)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methyl-2-(methylsulfonyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 183554-03-2 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 183554-15-6 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(6-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 183594-99-2 CAPLUS  
CN Carbamic acid, [5-[[[(2R,3S)-[3-[[[(2S)-3,3-dimethyl-1-oxo-2-[(1-pyrrolidinylacetyl)amino]butyl]amino]-2-hydroxy-4-phenylbutyl]amino]sulfonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183812-53-5 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(6-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]-, dihydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 183812-50-2P 183812-51-3P  
RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(benzo fused heterocyclic sulfonyl halide intermediates for the preparation of amino acids as HIV protease inhibitors)  
RN 183812-50-2 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1R)-2-[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-1-(methylsulfonyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183812-51-3 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1R)-1-[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methyl-2-(methylsulfonyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1999:671016 CAPLUS  
DOCUMENT NUMBER: 131:286828  
TITLE: Preparation of amino acid hydroxyethylamino sulfonamides as retroviral protease inhibitors  
INVENTOR(S): Getman, Daniel P.; Decrescenzo, Gary A.; Freskos, John N.; Vazquez, Michael L.; Sikorski, James A.; Devadas, Balakudru; Nagarajan, Srinivasan R.; Brown, David L.; McDonald, Joseph J.  
PATENT ASSIGNEE(S): G.D. Searle and Co., USA  
SOURCE: U.S., 96 pp., Cont.-in-part of U.S. Ser. No. 402,287, abandoned.  
CODEN: USXKAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 5  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5968970	A	19991019	US 1998-894900	19980102
WO 9628463	A1	19960919	WO 1996-US2684	19960307
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
EP 1258491	A1	20021120	EP 2002-11526	19960307
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
US 2002111368	A1	20020815	US 2001-836443	20010418
US 6458785	B2	20021001	US 1995-402287	19950310
PRIORITY APPLN. INFO.: WO 1996-US2684 B2 19960307				
US 1995-474052 A2 19950607				
EP 1996-907135 A3 19960307				
US 1999-451920 A3 19991201				

OTHER SOURCE(S): MARPAT 131:286828  
GI



AB Amino acid hydroxyethylamino sulfonamide compds. I [X = CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>; R<sub>1</sub> = alkyl, alkenyl, alkynyl, hydroxy-, alkoxy-, or cyanoalkyl, imidazolylmethyl, CH<sub>2</sub>CONH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>CONH<sub>2</sub>, CH<sub>2</sub>SO<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>SO<sub>2</sub>Me, CH<sub>2</sub>SO<sub>2</sub>Me, CH<sub>2</sub>SO<sub>2</sub>Me, CH<sub>2</sub>SO<sub>2</sub>Me; R<sub>2</sub> = alkyl, aralkyl, alkylthioalkyl, arylthioalkyl, cycloalkylalkyl, R<sub>3</sub> = alkyl, cycloalkyl, cycloalkylmethyl; R<sub>4</sub> = aryl, benzo-fused heterocyclyl or heterocyclyl; R<sub>10</sub> = H, alkyl, hydroxy- or alkoxyalkyl; R<sub>11</sub> = H, alkyl, hydroxyalkyl,


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
alkoxyalkyl, benzyl, imidazolylmethyl, CH<sub>2</sub>CONH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>CONH<sub>2</sub>, CH<sub>2</sub>SO<sub>2</sub>Me, CH<sub>2</sub>SO<sub>2</sub>Me, CH<sub>2</sub>SO<sub>2</sub>Me; R<sub>12</sub> = H, hydroxyalkyl, alkoxyalkyl, R<sub>13</sub>, R<sub>14</sub> = H, OH, alkoxy, 2-hydroxyethoxy, hydroxyalkyl, or alkoxyalkyl or R<sub>13</sub> and R<sub>14</sub> together form (un)substituted benzo or heteroaryl or their pharmaceutically acceptable salts, prodrugs, or esters were prepd. as retroviral protease inhibitors. Thus, 2S-(pyrrolidinoacetamido)-N-[2R-hydroxy-3-[(N1-(2-methylpropyl)-N1-(2,3-dihydrobenzofuran-5-ylsulfonyl)amino]-1S-(phenylmethyl)propyl]-3S-methylpentanamide was prepd. and showed IC<sub>50</sub> = 2 nM for inhibition of HIV protease.  
IT 183812-51-3P  
RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of amino acid hydroxyethylamino sulfonamides as retroviral protease inhibitors)  
RN 183812-51-3 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1R)-1-[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methyl-2-(methylsulfonyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 174303-65-2P 183553-47-1P 183553-66-4P  
183553-78-8P 183553-82-4P 183553-86-8P  
183553-87-9P 183553-89-1P 183553-94-8P  
183554-03-2P 183554-04-3P 183554-05-4P  
183554-07-6P 183554-15-6P 183554-99-2P  
183812-50-2P 183812-53-3P  
RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of amino acid hydroxyethylamino sulfonamides as retroviral protease inhibitors)  
RN 174303-65-2 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1R)-1-[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 183553-47-1 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-3-[(2,3-dihydro-5-benzofuran-1-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183553-66-4 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183553-78-8 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



RN 183553-89-1 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1R)-2-[[[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-1-(methylsulfonyl)methyl]-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 183553-94-8 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1R)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methyl-2-(methylsulfonyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 183553-82-4 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183553-86-8 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183553-87-9 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 183554-03-2 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183554-04-3 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10760125


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
 RN 183554-05-4 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[[[(2,3-dihydro-5-benzofuran-2-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183554-07-6 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-3-butynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183554-15-6 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(6-benzothiazol-2-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)  
 RN 183812-53-5 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(6-benzothiazol-2-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)



● 2 HCl


RN 183594-99-2 CAPLUS  
 CN Carbanic acid, [5-[[[(2R,3S)-[3-[[[(2S)-3,3-dimethyl-1-oxo-2-[(1-pyrrolidinyl)acetyl]amino]butyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183812-50-2 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1R)-2-[[[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-1-[(methylsulfonyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS ON STN  
 ACCESSION NUMBER: 1998:392091 CAPLUS  
 DOCUMENT NUMBER: 129:41411  
 TITLE: Preparation of amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors  
 INVENTOR(S): Getman, Daniel P.; Decrescenzo, Gary A.; Freskos, John N.; Vazquez, Michael L.; Sikorski, James A.; Devadas, Balekudru; Nagarajan, Srinivasan; Brown, David L.; McDonald, Joseph J.  
 PATENT ASSIGNEE(S): G.D. Searle and Co., USA  
 SOURCE: U.S., 93 pp., Cont.-in-part of U. S. Ser. No. 402,287, abandoned.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 5  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5756533	A	19980526	US 1995-474052	19950607
CA 2215061	AA	19960919	CA 1996-2215061	19960307
WO 9628463	A1	19960919	WO 1996-US2684	19960307
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
AU 9650294	A1	19961002	AU 1996-50294	19960307
AU 705268	B2	19990520		
EP 813542	A1	19971229	EP 1996-907135	19960307
EP 813542	B1	20021016		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
CN 1186499	A	19980701	CN 1996-193620	19960307
JP 2001513746	T2	20010904	JP 1996-527648	19960307
AT 226213	E	20021115	AT 1996-907135	19960307
EP 1258491	A1	20021120	EP 2002-11526	19960307
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
PL 184748	B1	20021231	PL 1996-322784	19960307
PT 813542	T	20030131	PT 1996-907135	19960307
ES 2187640	T3	20030616	ES 1996-907135	19960307
EE 4349	B1	20040816	EE 1997-201	19960307
NO 9704148	A	19971027	NO 1997-4148	19970909
US 5965601	A	19991012	US 1998-33897	19980303
US 6140505	A	20001031	US 1998-80928	19980519
US 6310080	B1	20011030	US 1999-451920	19991201
US 2002111368	A1	20020815	US 2001-836443	20010418
US 6458785	B2	20021001		
US 2003216435	A1	20031120	US 2002-200589	20020723
US 6730669	B2	20040504		
US 2004260095	A1	20041223	US 2004-760125	20040120
PRIORITY APPLN. INFO.:			US 1995-402287	B2 19950310
			US 1995-391873	B2 19950222
			US 1995-474052	A 19950607
			EP 1996-907135	A3 19960307
			WO 1996-US2684	W 19960307
			US 1998-80928	A1 19980519

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 US 1999-451920 A3 19991201  
 US 2001-836443 A1 20010418  
 US 2002-200589 A1 20020723

OTHER SOURCE(S): MARPAT 129:41411  
 GI




AB Amino acid hydroxyethylamino sulfonamide compds. I (X = CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>; R<sub>1</sub> = alkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cyanoalkyl, imidazolylmethyl, CH<sub>2</sub>CONH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>CONH<sub>2</sub>, CH<sub>2</sub>SH, CH<sub>2</sub>SHMe or their sulfone or sulfoxide derivatives; R<sub>2</sub> = alkyl, aralkyl, alkylthioalkyl, arylthioalkyl, cycloalkylalkyl; R<sub>3</sub> = alkyl, cycloalkyl, cycloalkylmethyl; R<sub>4</sub> = aryl, benzo-fused heteroaryl or heterocyclyl; R<sub>5</sub> = H, alkyl, hydroxyalkyl, alkoxyalkyl; R<sub>6</sub> = H, alkyl, hydroxyalkyl, alkoxyalkyl, benzyl, imidazolylmethyl, CH<sub>2</sub>CONH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>CONH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>SH, CH<sub>2</sub>SHMe or their sulfone or sulfoxide derivs.; R<sub>7</sub> = H, hydroxyalkyl, alkoxyalkyl; R<sub>8</sub>, R<sub>9</sub> = H, OH, alkoxy, 2-hydroxyethoxy, hydroxyalkyl, alkoxyalkyl; or R<sub>7</sub> and R<sub>8</sub> or R<sub>8</sub> and R<sub>9</sub> form a heteroaryl or benzo radical) were prepared as retroviral protease inhibitors. Thus, 2S-1-(pyrrolidin-1-yl)acetamino-N-[(2R-hydroxy-3-[(1S)-(2-methylpropyl)]-N-[(2,3-dihydrobenzofuran-5-ylsulfonyl)amino]-1S-(phenylmethyl)propyl]-3S-methylpentanamide, prepared from N-[3S-benzylloxycarbonylamino-2R-hydroxy-4-phenylbutyl]-N-isobutylamine, tert-Bu bromoacetate, pyrrolidine, and 2,3-dihydrofuran, showed HIV protease inhibitory activity IC<sub>50</sub> = 2 nM.

IT 174303-65-2P 183553-47-1P 183553-66-4P  
 183553-78-8P 183553-82-4P 183553-86-8P  
 183553-87-9P 183553-89-1P 183553-94-8P  
 183554-03-2P 183554-04-3P 183554-05-4P  
 183554-07-6P 183554-15-6P 183554-36-1P  
 183554-39-4P 183554-41-8P 183554-43-0P  
 183554-45-2P 183554-47-4P 183554-50-9P  
 183554-53-2P 183554-55-4P 183554-57-6P  
 183554-60-1P 183554-63-4P 183554-65-6P  
 183554-67-8P 183554-68-9P 183554-70-3P  
 183594-99-2P 183812-50-2P 183812-51-3P  
 183812-53-5P  
 RL: BAC (Biological activity or effector, except adverse); RSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors)

RN 174303-65-2 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 ylulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183553-82-4 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183553-86-8 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183553-87-9 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 NAME)

Absolute stereochemistry.




RN 183553-47-1 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-3-[(2,3-dihydro-5-benzofuranyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183553-66-4 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183553-78-8 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



RN 183553-89-1 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1R)-2-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-1-[(methylsulfonyl)methyl]-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 183553-94-8 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1R)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methyl-2-(methylsulfonyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 183554-03-2 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)phenylsulfonyl]amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183554-04-3 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl]amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● 2 HCl

RN 183554-36-1 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)phenylsulfonyl]amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183554-39-4 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)phenylsulfonyl]amino]-1-(phenylmethyl)propyl]amino]carbonyl]-3-butynyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 183554-05-4 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(2,3-dihydro-5-benzofuranyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183554-07-6 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-3-butynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183554-15-6 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(6-benzothiazolyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]-, dihydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 183554-41-8 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl]amino]-1-(phenylmethyl)propyl]amino]carbonyl]-3-butynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183554-43-0 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(2,3-dihydro-5-benzofuranyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183554-45-2 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(2,3-dihydro-5-benzofuranyl)sulfonyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-3-butynyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 183554-47-4 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(6-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183554-50-9 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-3-[(6-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183554-53-2 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(6-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
methylpropyl (2-naphthalenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183554-63-4 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(2-naphthalenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-3-butynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183554-65-6 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183554-67-8 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
(phenylmethyl)propyl]amino]carbonyl]-3-butynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183554-55-4 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(2-naphthalenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183554-57-6 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(2-naphthalenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183554-60-1 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(2-naphthalenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 183554-68-9 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-3-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183554-70-3 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-3-butynyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183594-99-2 CAPLUS  
CN Carbamic acid, [5-[[[(2R,3S)-3-[(2S)-3,3-dimethyl-1-oxo-2-[(1-pyrrolidinylacetyl)amino]butyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 183812-50-2 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1R)-2-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-1-(methylsulfonyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183812-51-3 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1R)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methyl-2-(methylsulfonyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183812-53-5 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:748344 CAPLUS  
DOCUMENT NUMBER: 126:19331  
TITLE: Preparation of peptide hydroxyethylaminosulfonamide analogs as retroviral protease inhibitors.  
INVENTOR(S): Getman, Daniel P.; Decrescenzo, Gary A.; Freskos, John N.; Vazquez, Michael L.; Sikorski, James A.; Devadas, Balakrishnan; Nagarajan, Srinivasan; Brown, David L.; McDonald, Joseph J.  
PATENT ASSIGNEE(S): G.D. Searle and Co., USA  
SOURCE: PCT Int. Appl., 212 pp.  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 5  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9628463	A1	19960919	WO 1996-US2684	19960307
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
US 5756533	A	19980526	US 1995-474052	19950607
AU 9650294	A1	19961002	AU 1996-50294	19960307
AU 705268	B2	19990520		
EP 813542	A1	19971229	EP 1996-907135	19960307
EP 813542	B1	20021016		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
BR 9607638	A	19980526	BR 1996-7638	19960307
JP 2001513746	T2	20010904	JP 1996-527648	19960307
AT 226213	E	20021115	AT 1996-907135	19960307
EP 1258491	A1	20021120	EP 2002-11526	19960307
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
PL 184748	B1	20021231	PL 1996-322784	19960307
EE 4349	B1	20040816	EE 1997-201	19960307
NO 9704148	A	19971027	NO 1997-4148	19970909
US 5968970	A	19991019	US 1998-894900	19981012
US 2002111368	A1	20020815	US 2001-836443	20010418
US 6458785	B2	20021001		

PRIORITY APPLN. INFO.:

US 1995-402287	A2	19950310
US 1995-474052	A2	19950607
EP 1996-907135	A3	19960307
WO 1996-US2684	W	19960307
US 1999-451920	A3	19991201


OTHER SOURCE(S):

MARPAT 126:19331

GI


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB Title compds. (I; n = 1, 2; R1 = alkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cyanoalkyl, imidazolylalkyl, CH2CONH2, CH2SOMe, etc.; R2 = alkyl, aralkyl, alkylthioalkyl, arylthioalkyl, cycloalkylalkyl, R3 = alkyl, cycloalkyl, cycloalkylmethyl, R4 = aryl, benzoheteroaryl; R10 = H, alkyl, hydroxyalkyl, alkoxyalkyl; R11 = H, alkyl, hydroxyalkyl, alkoxyalkyl, PhCH2, imidazolylmethyl, CH2CH2CONH2, CH2CH2SOMe, etc.; R12 = H, hydroxyalkyl, alkoxyalkyl; R13, R14 = H, OH, alkoxy, 2-hydroxyethoxy, hydroxyalkyl, alkoxyalkyl; R12R13, R13R14 = atoms to form 5-6 membered heteroaryl or benzo rings), were prepared. Thus, title compound (II), prepared by solution phase means, inhibited HIV protease with IC50 = 2 nM.


IT 174303-65-2P 183553-47-1P 183553-66-4P  
183553-78-8P 183553-82-4P 183553-86-8P  
183553-87-9P 183553-89-1P 183553-94-8P  
183554-03-2P 183554-04-3P 183554-05-4P  
183554-07-6P 183554-15-6P 183554-36-1P  
183554-39-4P 183554-41-8P 183554-43-0P  
183554-45-2P 183554-47-4P 183554-50-9P  
183554-53-2P 183554-55-4P 183554-57-6P  
183554-60-1P 183554-63-4P 183554-65-6P  
183554-67-8P 183554-68-9P 183554-70-3P  
183554-99-2P 183554-100-2P 183554-101-3P  
183554-102-4P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of amino acid hydroxyethylaminosulfonamide retroviral protease inhibitors)

RN 174303-65-2 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methyl-2-(methylsulfonyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 183553-47-1 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-3-[(2,3-dihydro-5-benzofuranyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183553-66-4 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183553-78-8 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


2-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183553-89-1 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1R)-2-[[[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-1-(methylsulfonyl)methyl]-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 183553-94-8 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1R)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methyl-2-(methylsulfonyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 183553-82-4 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183553-86-8 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183553-87-9 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 183554-03-2 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183554-04-3 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 183554-05-4 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[[[2,3-dihydro-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183554-07-6 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-3-butynyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183554-15-6 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(6-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● 2 HCl

RN 183554-36-1 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183554-39-4 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-3-butynyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 183554-41-8 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-3-butynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183554-43-0 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[[[2,3-dihydro-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183554-45-2 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[[[2,3-dihydro-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-3-butynyl]- (9CI) (CA INDEX NAME)

Page 18

Saeed


L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 183554-47-4 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(6-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183554-50-9 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-3-[(6-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183554-53-2 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(6-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-3-butynyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 183554-55-4 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(2-naphthalenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183554-57-6 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(2-naphthalenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183554-60-1 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(2-naphthalenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 183554-68-9 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S,2S)-1-[[[(1S,2R)-3-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183554-70-3 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-3-butynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183594-99-2 CAPLUS  
CN Carbamic acid, [5-[[[(2R,3S)-3-[[[(2S)-3,3-dimethyl-1-oxo-2-[(1-pyrrolidinyl)amino]butyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
Absolute stereochemistry.


RN 183554-63-4 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(2-naphthalenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]carbonyl]-3-butynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183554-65-6 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183554-67-8 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 183812-50-2 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1R)-2-[[[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-1-[(methylsulfonyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183812-51-3 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1R)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methyl-2-(methylsulfonyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183812-53-5 CAPLUS  
CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:153437 CAPLUS  
 DOCUMENT NUMBER: 124:220480  
 TITLE: Retroviral protease inhibitor combinations  
 INVENTOR(S): Bryant, Martin L.; Potts, Karen E.; Smidt, Mary; Tucker, Simon P.  
 PATENT ASSIGNEE(S): G.D. Searle and Co., USA  
 SOURCE: PCT Int. Appl., 64 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9533464	A2	19951214	WO 1995-US6673	19950602
WO 9533464	A3	19960104		
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2191948	AA	19951214	CA 1995-2191948	19950602
AU 9526510	A1	19960104	AU 1995-26510	19950602
AU 696299	B2	19980903		
EP 762880	A1	19970319	EP 1995-921428	19950602
BR 9507912	A	19970812	BR 1995-7912	19950602
CN 1166786	A	19971203	CN 1995-194464	19950602
HU 76979	A2	19980128	HU 1996-3328	19950602
JP 10505324	T2	19980526	JP 1995-501057	19950602
NZ 287702	A	20000623	NZ 1995-287702	19950602
US 6100277	A	20000808	US 1995-458154	19950602
FL 180070	B1	20001229	PL 1995-317425	19950602
RU 2166317	C2	20010510	RU 1997-100123	19950602
NO 9605136	A	19970120	NO 1996-5136	19961202
FI 9604835	A	19970129	FI 1996-4835	19961203
US 2003207813	A1	20031106	US 2002-253899	20020925
PRIORITY APPLN. INFO.:				
			US 1994-253638	A2 19940603
			WO 1995-US6673	W 19950602
			US 1996-737960	B1 19961209

AB A method is disclosed for the treatment of mammalian retrovirus infections, e.g. HIV, using combinations of retroviral protease inhibitors which are effective in preventing the replication of the retroviruses in vitro or in vivo. In particular, the invention provides protease inhibitor compds. used in combination therapy with other protease inhibitor compds. Also disclosed is combination therapy with a combination of protease inhibitors and antiviral agents other than protease inhibitors. Preparation and activity of selected inhibitors is included.


IT 174303-65-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (retroviral protease inhibitor combinations, and protease inhibitor prepn.)

RN 174303-65-2 CAPLUS  
 CN 1-Pyrrolidineacetamide, N-[(1S)-1-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10760125

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

31.44

192.98

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-4.38

-4.38

STN INTERNATIONAL LOGOFF AT 12:40:19 ON 30 MAY 2005